Our unique team of experts brings together experience, passion and expertise.



Jonathan Lane

General Manager

With a background in molecular biology, Jonathan has worked in biotechnology for over 20 years. After a short but diverse research career, he moved into patent management and business development/licensing roles before co-founding NanoGenics.


Dr Simon Newman

Chief Scientific Officer

As Chief Scientific Officer of NanoGenics, Simon is responsible for the ongoing development of the in-house product pipeline and the continued development of the LipTide platform. Simon has led oncology drug discovery projects and new company spinouts at Imperial College London for ten years. He has published over 60 peer-reviewed papers, which have been cited over 2000 times. Simon has worked with Ipsen, Sterix, and Oxandia Ltd and was Director of Research for Target Ovarian Cancer.


Paul Murray

Executive Chairman

Paul is a chartered accountant with nearly 30 years of experience in the private equity market, having been a director of 3i PLC and a partner in Deutsche Bank’s private equity business. Paul now runs his own private equity fund.

Scientific Advisory Board

Prof Alexander Mullen

Serving as the Professor of Pharmacy Practice at University of Strathclyde, Alexander has an extensive research portfolio, encompassing oral and vesicular drug delivery technologies, drug eluting stents, liposomes, vaginal and vaccine delivery systems.

Dr Simon Newman
Dr Cunthia Yu-Wai-Man